Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial
European Journal of Neurology2020Vol. 27(5), pp. 841–848
Citations Over TimeTop 10% of 2020 papers
Nicolas Martinez‐Majander, George Ntaios, Y. Y. Liu, Pauli Ylikotila, Heikki Joensuu, J. Saarinen, Kanjana Perera, Joan Martí‐Fàbregas, Ángel Chamorro, Salvatore Rudilosso, Luís Prats‐Sánchez, Scott D. Berkowitz, Hardi Mundl, Ellison Themeles, Marjaana Tiainen, Andrew M. Demchuk, Scott E. Kasner, Robert G. Hart, Turgut Tatlisumak, the NAVIGATE ESUS investigators
Abstract
Our exploratory analyses show that patients with embolic stroke of undetermined source and a history of cancer had similar rates of recurrent ischaemic strokes and all-cause mortality during aspirin and rivaroxaban treatments and that aspirin appeared safer than rivaroxaban in cancer patients regarding major bleeds. www.clinicaltrials.gov (NCT02313909).
Related Papers
- → Assays for Measuring Rivaroxaban: Their Suitability and Limitations(2010)157 cited
- → THE ROLE OF ASPIRIN AND WARFARIN IN IHD PREVENTION.(1998)
- Cause analysis of secondary prevention failure on brain ischemic stroke by aspirin(2007)
- → Faculty Opinions recommendation of Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.(2010)
- → Appropriate Use of Aspirin in the Primary and Secondary Prevention: Results From the ASSOS Study(2022)